Press Releases

Date Title
Aug 08, 2022 Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update
– ONC201 Phase 3 ACTION Study Planned to Initiate This Year – –~$32M in Revenue from International TEMBEXA Agreements Recently Recognized– – U.S. Anti-Trust Clearance Obtained for Sale of TEMBEXA to Emergent BioSolutions – – Conference Call at 4:30 p.m. ET Today – DURHAM, N.C. , Aug.
Aug 08, 2022 Chimerix Appoints Christopher L. Jordan as Vice President, Regulatory Affairs
Brings 30 Years of Experience as a Former Endocyte and Novartis Regulatory Executive DURHAM, N.C. , Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly
Aug 02, 2022 Chimerix to Present at Wedbush PacGrow Healthcare Conference
DURHAM, N.C. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that Chimerix management will participate in the Targeted
Aug 01, 2022 Chimerix to Report Second Quarter 2022 Financial Results and Provide an Operational Update on August 8, 2022
DURHAM, N.C. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on
Jun 24, 2022 Chimerix Announces TEMBEXA Procurement Agreement for Approximately $25.3 Million with Public Health Agency of Canada
DURHAM, N.C. , June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract
Jun 23, 2022 Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement
DURHAM, N.C. , June 23, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced a $9.3 million agreement to procure TEMBEXA ®
Jun 01, 2022 Chimerix to Present at Jefferies Global Healthcare Conference
DURHAM, N.C. , June 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer, will present
May 17, 2022 Chimerix to Present at H.C. Wainwright Global Investment Conference
DURHAM, N.C. , May 17, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer, will present a
May 16, 2022 Chimerix Reports First Quarter 2022 Financial Results and Provides Operational Update
– Receiving up to $337.5 Million plus Royalties for Sale of Worldwide Rights of TEMBEXA to Emergent BioSolutions – – Initiation of Phase 3 Randomized Study of ONC201 in H3 K27M Mutant Glioma Expected in 2022 – – DSTAT Development Program Terminated; Resources Focused on Imipridone Platform – –
May 16, 2022 Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up to $337.5 Million plus Royalties
– $225 Million in Upfront Proceeds Secures Substantial Capital to Fund Operations and Allows for Participation in Future Economics – – Transaction Allows for Focus on Development Pipeline – – Positions TEMBEXA with Leading Global Biodefense Partner to Maximize Long Term Value – DURHAM, N.C.
Displaying 1 - 10 of 19
  • Print
  • Email Alerts
  • RSS Feeds
  • Search
  • Share